INKT
NASDAQMiNK Therapeutics Inc.
Price$10.82-1.19 (-10.62%)
2026-07-162026-10-16
News · 26 weeks38-20%
2026-04-192026-10-11
Mix1690d
- Insider6(38%)
- Other4(25%)
- SEC Filings4(25%)
- Earnings2(13%)
Latest news
25 items- INSIDERSEC Form 4 filed by MiNK Therapeutics Inc.4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- SECSEC Form 144 filed by MiNK Therapeutics Inc.144 - MiNK Therapeutics, Inc. (0001840229) (Subject)
- PRMiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations a
- PRMiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell TherapyClinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its clinical-stage agenT-797 iNKT platform has been selected as a therapeutic cell
- INSIDERDirector Wiinberg Ulf was granted 1,279 shares, increasing direct ownership by 6% to 23,929 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- INSIDERDirector Behner Peter was granted 1,485 shares, increasing direct ownership by 6% to 24,404 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- INSIDERDirector Holcomb John Bradley was granted 1,233 shares, increasing direct ownership by 36% to 4,691 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- INSIDERDirector Ryan Barbara was granted 1,622 shares, increasing direct ownership by 7% to 23,591 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- INSIDERDirector Corvese Brian was granted 1,633 shares, increasing direct ownership by 3% to 54,770 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- SECSEC Form S-8 filed by MiNK Therapeutics Inc.S-8 - MiNK Therapeutics, Inc. (0001840229) (Filer)
- SECSEC Form 10-Q filed by MiNK Therapeutics Inc.10-Q - MiNK Therapeutics, Inc. (0001840229) (Filer)
- SECMiNK Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)
- PRMiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung InjuryFirst patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor supportClinical recovery and biologic readouts moved in the same direction; serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery and tissue repair; no major serious adverse events were attributed to agenT-797Launched international paid named-patient access program established for physicians to request access to agenT-797, subject to per-patient regulatory authorization; building cross-border infrastructure and access NE
- PRMiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research SymposiumFirst patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor supportAnalysis of blood and lung fluid showed signals of infection control and biological changes associated with immune recovery, tissue repair and pulmonary recoveryMiNK initiated dosing immediately after regulatory clearance; a pace made possible by our therapy that ships from inventory, with no apheresis, patient-specific manufacturing, HLA matching or lymphodepletionEnrollment continues in Lviv with U.S. sites opening; additional data are expected in early 2027 NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Thera
- PRMiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business UpdatesNEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update focused on the clinical advancement of agenT-797, MiNK’s off-the-shelf allogeneic iNKT cell therapy, in acute lung injury. The update will include new clinical data on the
- PRAgenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon CancerPreviously announced oversubscribed $85 million private placement, with up to an additional $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN execution ROBBIN addresses approximately 38,000 newly diagnosed U.S. patients annually and an estimated annual U.S. sales opportunity of more than $7 billion; initiation and first patient dosing are expected in the first quarter of 2027 Previously reported NEST and UNICORN findings provided the direct clinical rationale for ROBBIN; recent advanced-disease updates reinforce the durability of BOT+BAL activity BOT+BAL access programs expanded across additional countries and treating institutions, contributing $
- SECMiNK Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)
- INSIDERDirector Ryan Barbara sold $19,141 worth of shares (1,500 units at $12.76), decreasing direct ownership by 6% to 21,969 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- PRMiNK Therapeutics Announces its Virtual 2026 Annual Shareholders MeetingNEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2026 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for gu
- INSIDERDirector Ryan Barbara was granted 3,063 shares, increasing direct ownership by 15% to 23,469 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- INSIDERDirector Holcomb John Bradley was granted 2,330 shares, increasing direct ownership by 207% to 3,458 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- INSIDERDirector Corvese Brian was granted 3,084 shares, increasing direct ownership by 6% to 53,137 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- INSIDERDirector Behner Peter was granted 2,804 shares, increasing direct ownership by 14% to 22,919 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- INSIDERDirector Wiinberg Ulf was granted 2,416 shares, increasing direct ownership by 12% to 22,650 units (SEC Form 4)4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
- PRA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc. (NASDAQ:GTBP) recently put its third drug into the clinic — and the entire company has at times been valued at a small fraction of that. The gap between what the company is doing in the lab and what the market is paying for it is the whole story here, and a milestone reached in mid-May has brought it into sharp focus.
INKT FAQ
7 questionsWhat does MiNK Therapeutics Inc. do?
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Where does INKT stock trade?
MiNK Therapeutics Inc. (INKT) is listed on NASDAQ.What sector and industry is INKT in?
MiNK Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did MiNK Therapeutics Inc. go public?
MiNK Therapeutics Inc. (INKT) completed its IPO in 2021.What are analysts saying about INKT?
MiNK Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $3500.00 price target on 2025-08-15. Recent price targets range from $1000.00 to $3500.00.What companies are similar to INKT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare INKT side-by-side with any of them on Quantisnow.How can I track INKT on Quantisnow?
Quantisnow aggregates MiNK Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INKT to receive live email and push alerts on every new disclosure.